PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsErythromycin lactobionate
Erythromycin lactobionate
Benzamycin, E.e.s, Ery-tab, Eryc, Erygel, Eryped, Erythrerm, Erythrocin, Erythromycin, Eryzole, Ilosone, Ilotycin, Pediazole (erythromycin lactobionate) is a small molecule pharmaceutical. Erythromycin lactobionate was first approved as Ilotycin on 1982-01-01. It is used to treat acne vulgaris, bacterial eye infections, bacterial infections, campylobacter infections, and chancroid amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
digestive system diseasesD004066
respiratory tract diseasesD012140
eye diseasesD005128
urogenital diseasesD000091642
skin and connective tissue diseasesD017437
Trade Name
FDA
EMA
E.e.s., Eryped, Erythrocin, Erythromycin ethylsuccinate, Erythromycin lactobionate (discontinued: E-mycin, E.e.s., Eryped, Erythrocin, Erythromycin, Erythromycin ethylsuccinate, Erythromycin lactobionate, Pediamycin, Wyamycin)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Erythromycin lactobionate
Tradename
Company
Number
Date
Products
ERYTHROCINHospiraN-050609 RX1986-09-24
1 products, RLD, RS
Show 2 discontinued
Erythromycin ethylsuccinate
Tradename
Company
Number
Date
Products
E.E.S.Carnegie PharmaceuticalsN-050207 RX1982-01-01
1 products, RLD
ERYPEDCarnegie PharmaceuticalsN-050207 RX1982-01-01
2 products, RLD, RS
Show 2 discontinued
Erythromycin ethylsuccinate
+
Sulfisoxazole acetyl
Tradename
Company
Number
Date
Products
PEDIAZOLERoss LaboratoriesN-050529 DISCN1982-01-01
1 products
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
benzamycinNew Drug Application2020-11-30
e.e.sNew Drug Application2011-04-18
e.e.s e.e.sANDA, New Drug Application2025-02-21
eryANDA2024-12-24
ery-pedNew Drug Application2024-12-24
ery-tabANDA2024-10-11
erygelNew Drug Application2018-06-21
erythrocin lactobionateANDA2024-02-22
erythrocin stearateANDA2015-07-31
erythromycinANDA2025-03-12
Show 9 more
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
acne vulgarisEFO_0003894D000152L70
bacterial infections—D001424A49
gonorrheaDOID_7551D006069A54
campylobacter infectionsEFO_0007190D002169—
whooping coughEFO_0000650D014917A37
chlamydia infectionsEFO_0007205D002690A74.9
streptococcal infectionsEFO_1001476D013290—
legionnaires' diseaseEFO_0007343D007877A48.1
urethritisEFO_0003878D014526N34
bacterial eye infections—D015818—
Show 7 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
D: Dermatologicals
— D10: Anti-acne preparations
— D10A: Anti-acne preparations for topical use
— D10AF: Antiinfectives for treatment of acne
— D10AF02: Erythromycin
— D10AF52: Erythromycin, combinations
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01F: Macrolides, lincosamides and streptogramins
— J01FA: Macrolides
— J01FA01: Erythromycin
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01A: Antiinfective ophthalmologics
— S01AA: Antibiotics, ophthalmologic
— S01AA17: Erythromycin
HCPCS
Code
Description
J1364
Injection, erythromycin lactobionate, per 500 mg
Clinical
Clinical Trials
2373 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———4————4
MalnutritionD044342EFO_0008572E40-E462————2
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameErythromycin lactobionate
INNerythromycin
Description
Erythromycin A is an erythromycin that consists of erythronolide A having 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl and 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl residues attahced at positions 4 and 6 respectively. It is an erythromycin and a cyclic ketone. It is functionally related to an erythronolide A. It is a conjugate base of an erythromycin A(1+).
Classification
Small molecule
Drug classantibiotics (Streptomyces strain)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O.O=C(O)[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO
Identifiers
PDB—
CAS-ID114-07-8
RxCUI4053
ChEMBL IDCHEMBL1200506
ChEBI ID—
PubChem CID12560
DrugBankDB00199
UNII ID63937KV33D (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Pfizer – Protalix BioTherapeutics
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 87,378 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
11,143 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use